Clinical Trials Logo

Osteosarcoma clinical trials

View clinical trials related to Osteosarcoma.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06162962 Completed - Osteosarcoma Clinical Trials

Oncological and Functional Outcomes in Lower Limb Osteosarcoma Pediatric Patient

Start date: January 1, 2000
Phase:
Study type: Observational

Retrospective analysis of specific characteristics of complications and long-term oncological and function outcomes in lower-limb osteosarcoma pediatric patients.

NCT ID: NCT05801887 Completed - Osteosarcoma Clinical Trials

Extracorporeal Shock Wave Therapy on Osteoblast-Like Cells In- Vitro Study

ESWT
Start date: October 22, 2021
Phase: N/A
Study type: Interventional

The idea of treating different deformities or diseases in the maxillofacial region with Extracorporeal Shockwave Therapy (ESWT) has recently become popular. It has been widely used in medical practice for the management of urolithiasis, cholelithiasis and in haead and neck region for sialolithiasis. The present study 'Extracorporeal Shock Wave Therapy on Osteoblast-Like Cells In-vitro study' will be done to explore and evaluate the effect of shockwaves. Further, Osteoblast-like cells will be assessed for Cell - Cell interaction and Cell Viability. It will be assessed using a scratch assay, Mtt assay and ATP analysis.

NCT ID: NCT05794594 Completed - Clinical trials for Osteosarcoma in Children

3D Printed Personalized Extendable Prosthesis

Start date: October 1, 2015
Phase:
Study type: Observational

The goal of this type of observational study is to investigate the preliminary effect of 3D printed personalized extendable prosthesis replacement on limb salvage in children with osteosarcoma. The main question it aims to answer is: Is 3D printed personalized extendable prosthesis replacement has a good outcome in limb salvage pediatric osteosarcoma?

NCT ID: NCT05277480 Completed - Effect of Drug Clinical Trials

Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)

OAIE
Start date: March 1, 2022
Phase: Phase 2
Study type: Interventional

Apatinib has led to positive responses in the treatment of osteosarcoma refractory to first-line chemotherapy. However, apatinib demonstrates only short-lived activity, and the disease control of musculoskeletal lesions is worse than that of pulmonary lesions. This treatment failure has been partly overcome by the addition of ifosfamide and etoposide (IE). We have ever retrospectively compared the activity of apatinib + IE in relapsed or refractory osteosarcoma in two sarcoma centers in China and concluded that for osteosarcoma with multiple sites of metastasis, apatinib + IE demonstrated clinically meaningful antitumor activity and delayed disease progression in patients with recurrent or refractory osteosarcoma after failure of chemotherapy. However to overcome the influence of other interventions on the outcome, we are currently performing a prospective trial to investigate this combination, from which more accurate data on this treatment strategy are expected.

NCT ID: NCT05101655 Completed - Osteosarcoma Clinical Trials

Construction of Microfluidic Exosome Chip for Diagnosis of Lung Metastasis of Osteosarcoma

Start date: October 1, 2020
Phase:
Study type: Observational

Use exosome microfluidic chips to establish a combination of exosome subgroup level (exosome barcode) markers for the early diagnosis of osteosarcoma lung recurrence, and establish the basis of microfluidic chip based exosome biomarker for monitoring the early therapeutic response of the second-line therapy for recurrent osteosarcoma.

NCT ID: NCT05093322 Completed - Lymphoma Clinical Trials

A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Start date: November 30, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of surufatinib, thereby identifying the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of surufatinib administered in combination with gemcitabine in pediatric patients with recurrent or refractory solid tumors or lymphoma. The study will be conducted in 2 parts.

NCT ID: NCT05093101 Completed - Osteosarcoma Clinical Trials

The Prognostic Value of Serum Biomarkers in Osteosarcoma

Start date: July 12, 2021
Phase:
Study type: Observational

Observational retrospective cohort study using laboratory data of blood tests prior to surgical and chemotherapy treatment and other histologic, clinical, and instrumental data related to patient history from digitized medical records and analysis of the same as predictors of outcomes.

NCT ID: NCT05024253 Completed - Osteosarcoma Clinical Trials

Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Will Change in Blood Loss and Transfusion Requirements.

Start date: August 2, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to investigate whether previously reported benefit of Tranexamic acid in pediatric orthopedic surgeries could be recapitulated in bone tumor surgeries or not through a double blinded randomized controlled trial done in children cancer hospital 57357.

NCT ID: NCT04974008 Completed - Bone Cancer Clinical Trials

Osteosarcoma Maintenance Therapy With OST31-164

OST-164-01
Start date: October 21, 2021
Phase: Phase 2
Study type: Interventional

Up to 45 Patients aged 12 to 39 with osteosarcoma (bone cancer) that had recurred in the lungs and has recently been surgically removed will be enrolled. Patients will receive OST31-164 infusions every 3 weeks over 48 weeks and be followed after that for 3 years.

NCT ID: NCT04963517 Completed - Bone Sarcoma Clinical Trials

Exercise Intervention for Bone Tumor Patients

proGAIT
Start date: August 7, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The proGait-study is a two-arm exercise intervention study for AYA-patients with lower extremity tumor endoprosthesis in the follow-up care. This clinical trial will investigate the effects of an 8-week personalized multi-modal exercise intervention of lower extremity muscles on gait quality in adolescents and young adults with cancer diagnosis beginning at least 12 months after endoprosthesis implantation.